INS and type 1 diabetes mellitus: Another randomized, double-blind, placebo-controlled trial involved 100 adult patients with T1D who had a BMI of ≥25 kg/m2 and HbA1c levels of ≥8% and were randomly assigned to receive liraglutide at a dose of 1.8 mg daily or a placebo alongside their insulin therapy for 24 weeks.